menu icon
Unmet Need

The need for multifactorial therapies

Retinal vascular diseases are a leading cause of vision loss worldwide. Among these diseases, age-related macular degeneration (AMD) affects nearly 200 million people worldwide, with 10 million affected by moderate to severe vision loss.1 The neovascular form of AMD (nAMD) accounts for approximately 90% of this vision loss.2

Three dominant angiogenic pathways mediated by VEGF-A, VEGF-C, and Ang-2 are known to contribute to nAMD. Today, the best treatment option for nAMD is repeated monthly injections of anti-VEGF drugs that predominantly target only 1 of these pathways: VEGF-A.

Cytokine compensation following
treatment with anti-VEGF monotherapy3

When the VEGF-A pathway is treated, both VEGF-C and Ang-2 can become more active in retinal vascular diseases, leading to suboptimal efficacy or become refractory and requiring more frequent treatment.3

While VEGF-A treatment is sufficient for many patients, only ~30% of patients have a form of nAMD that responds optimally to VEGF-A monotherapy.4-6 Therefore, most patients with nAMD might benefit from a treatment that could simultaneously target VEGF-A, VEGF-C, and Ang-2.

What if it were possible to create a single
multispecific, fully human biologic that
effectively neutralizes all 3 dominant
disease-causing pathways with one therapy
(VEGF-A, VEGF-C, and Ang-2)?

RO-104

RO-104 targets all 3 dominant angiogenic
pathways in retinal vascular disease

RO-104 is a first-in-class Tri-Mod biologic designed to neutralize all 3 dominant angiogenic pathways to provide improved outcomes and extended disease remission for patients with nAMD.

Developed using our proprietary Rev-Mod Platform, RO-104 is the first and only candidate to singularly target the 3 dominant clinically validated pathways that lead to disease progression in nAMD.

RO-104 binds to VEGF-A, VEGF-C, and Ang-2 with high, matched affinity and demonstrates intended efficacy in established animal models.7

Pipeline

A pipeline of discovery and development

Leveraging our proprietary Rev-Mod Platform, RevOpsis is committed to developing a compelling pipeline of therapeutic candidates to address unmet needs in prevalent chronic multifactorial ophthalmic diseases. Our solutions for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), retinal vein occlusion (RVO), dry AMD, uveitic macular edema, and thyroid eye disease will be poised to address unmet needs in millions of patients worldwide.

The proprietary Rev-Mod Platform can be applied across therapeutic categories, including diseases of the immune system, autoimmune diseases, and oncology. Multi-Mod biologics can be specifically designed to address more clinically validated interlinked and compensatory disease pathways than traditional antibodies that can only target one pathway.

Learn more about how the Rev-Mod Platform can be applied across therapeutic areas.

Learn more
Reference: 1. World Health Organization. World Report of Vision. World Health Organization;2019. 2. Pugazhendhi A, et al. Int J Mol Sci. 2021;22(3):1170. 3. Cabral T, et al. Ophthalmol Retina. 2018;2(1):31-37. 4. Lux A, et al. Br J Ophthalmol. 2007;91(10):1318-1322. 5. Mettu PS, et al. Prog Retin Eye Res. 2021;82:100906. 6. Cohen SY, et al. Br J Ophthalmol. 2007;91(9):1173-1176. 7. Data on file. RevOpsis.